PD-1 antibody

Phase 3

PD-1 antibody is one of 49 therapeutic programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Esophageal Squamous Cell CarcinomaRecruiting

Rectal CancerActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Recruiting

Rectal CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

241 competitors in Esophageal Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

30 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

31 3

Camptosar

Pfizer

Phase 3

11 4

Keytruda

Merck & Co.

Phase 3

8 5

Eloxatin

Teva

Phase 3

4 6

Imfinzi

AstraZeneca

Phase 3

4 7

Tecentriq

Roche

Phase 3

2 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

9 9

Bayer Aspirin

Bayer

Phase 3

1 10

Taxotere

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Rectal Cancer

NCT06507371

Q1 2029

Phase 2Recruiting

Esophageal Squamous Cell Carcinoma

NCT07403136

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

An Open-Label, Randomized Phase II Study of Becotatug Vedotin With or Without PD-1 Inhibitor Immunotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Refractory to Previous Immunochemotherapy

Recruiting·FFudan University·Phase 2·NCT07403136·104 enrolled

Rectal Cancer1 trial

Node-sparing Modified Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Locally Advanced of Middle and Low Rectal Cancer : An Randomized, Prospective, Multicenter, Open-label, Phase III Clinical Trial (mRCAT-III)

Active, not recruiting·SSir Run Run Shaw Hospital·Phase 3·NCT06507371·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PD-1 antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for PD-1 antibody. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sir Run Run Shaw Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSir Run Run Shaw Hospital

PD-1 antibody

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

Rectal Cancer1 trial

References

Drug Info

Quick Facts

Related News